Pfizer's "Online Resources" Are Over The Line For FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Reintegrating the principles in its seminal citations of search engine ads, DDMAC tells Pfizer to stop including "riskless" links for named drugs as part of its Lipitor website.
You may also be interested in...
Can Bad Ad Program's Light Penetrate Murky CME, Clinical Trial Practices?
The "Bad Ad" program already has proven to be a great success in motivating health care providers to report well-known forms of false or misleading drug promotion, such as ads that overstate efficacy and minimize risks, but can it help address more subtle and difficult-to-detect forms of questionable drug promotion, such as those that are hidden in drugmakers' support of professional education and clinical trials?
FDA's Internet Promotion Policy: Christmas Cards In Lieu Of Guidance?
Industry will ring in the New Year with no more guidance from FDA on Internet and social media promotion than the warning and untitled letters that FDA has issued during the past several years.
Internet Searching May Get ‘Riskier’ For Patients After FDA Citations
“Sponsored searches” need to contain risk information, agency tells 14 firms in letters covering 48 products.